Arch Biopartners Inc. (ACHFF)
USD 1.24
(0.81%)
USD 1.24
(0.81%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -128.99 Thousand CAD | 74.35% |
| 2022 | -502.87 Thousand CAD | -235.72% |
| 2021 | -149.79 Thousand CAD | 92.94% |
| 2020 | -2.12 Million CAD | -51.26% |
| 2019 | -1.4 Million CAD | 6.6% |
| 2018 | -1.5 Million CAD | -145.98% |
| 2017 | -610.72 Thousand CAD | -48.29% |
| 2016 | -411.84 Thousand CAD | -19.19% |
| 2015 | -345.54 Thousand CAD | -96.3% |
| 2014 | -176.02 Thousand CAD | -288.11% |
| 2013 | -45.35 Thousand CAD | 0.0% |
| 2012 | - CAD | 100.0% |
| 2011 | -9779.00 CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 740.29 Thousand CAD | 31.29% |
| 2007 | 563.86 Thousand CAD | -11.85% |
| 2006 | 639.67 Thousand CAD | 28.14% |
| 2005 | 499.21 Thousand CAD | -55.78% |
| 2004 | 1.12 Million CAD | 21.06% |
| 2003 | 932.57 Thousand CAD | 153.74% |
| 2002 | -1.73 Million CAD | -101880.76% |
| 2001 | 1705.00 CAD | -99.64% |
| 2000 | 471.06 Thousand CAD | 481.92% |
| 1999 | 80.95 Thousand CAD | -44.92% |
| 1998 | 146.97 Thousand CAD | 167.63% |
| 1997 | 54.91 Thousand CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 128.41 Thousand CAD | 104.38% |
| 2024 Q2 | -561.26 Thousand CAD | -537.08% |
| 2024 Q3 | -473.1 Thousand CAD | 15.71% |
| 2023 Q2 | -632.29 Thousand CAD | -1829.13% |
| 2023 Q3 | -196.51 Thousand CAD | 68.92% |
| 2023 Q4 | -2.93 Million CAD | -1391.14% |
| 2023 FY | -128.99 Thousand CAD | 74.35% |
| 2023 Q1 | -32.77 Thousand CAD | 96.6% |
| 2022 Q4 | -964.33 Thousand CAD | -1461.6% |
| 2022 Q3 | -61.75 Thousand CAD | 75.02% |
| 2022 Q2 | -247.21 Thousand CAD | -948.01% |
| 2022 Q1 | 29.15 Thousand CAD | -96.68% |
| 2022 FY | -502.87 Thousand CAD | -235.72% |
| 2021 Q1 | -1.34 Million CAD | -0.45% |
| 2021 Q4 | 878.69 Thousand CAD | -23.57% |
| 2021 FY | -149.79 Thousand CAD | 92.94% |
| 2021 Q3 | 1.14 Million CAD | 242.05% |
| 2021 Q2 | -809.33 Thousand CAD | 39.6% |
| 2020 Q1 | -580.07 Thousand CAD | -12.3% |
| 2020 Q2 | -71.18 Thousand CAD | 87.73% |
| 2020 Q3 | -338.77 Thousand CAD | -375.92% |
| 2020 Q4 | -1.33 Million CAD | -293.78% |
| 2020 FY | -2.12 Million CAD | -51.26% |
| 2019 Q1 | -723.27 Thousand CAD | -42.29% |
| 2019 FY | -1.4 Million CAD | 6.6% |
| 2019 Q4 | -516.54 Thousand CAD | -1023.61% |
| 2019 Q2 | -268.41 Thousand CAD | 62.89% |
| 2019 Q3 | -45.97 Thousand CAD | 82.87% |
| 2018 Q2 | -486.88 Thousand CAD | -87.47% |
| 2018 Q3 | -247.37 Thousand CAD | 49.19% |
| 2018 Q1 | -259.71 Thousand CAD | -36.24% |
| 2018 FY | -1.5 Million CAD | -145.98% |
| 2018 Q4 | -508.32 Thousand CAD | -105.48% |
| 2017 Q1 | -175.17 Thousand CAD | -28.93% |
| 2017 Q2 | -30.58 Thousand CAD | 82.54% |
| 2017 Q4 | -190.62 Thousand CAD | 11.54% |
| 2017 FY | -610.72 Thousand CAD | -48.29% |
| 2017 Q3 | -215.48 Thousand CAD | -604.49% |
| 2016 FY | -411.84 Thousand CAD | -19.19% |
| 2016 Q2 | -80.88 Thousand CAD | -8.03% |
| 2016 Q3 | -120.22 Thousand CAD | -48.64% |
| 2016 Q4 | -135.87 Thousand CAD | -13.02% |
| 2016 Q1 | -74.86 Thousand CAD | 50.85% |
| 2015 FY | -345.54 Thousand CAD | -96.3% |
| 2015 Q1 | -51.31 Thousand CAD | -2019.72% |
| 2015 Q4 | -152.31 Thousand CAD | -88.22% |
| 2015 Q3 | -80.92 Thousand CAD | 5.01% |
| 2015 Q2 | -85.19 Thousand CAD | -66.02% |
| 2014 Q1 | -36.78 Thousand CAD | -690.03% |
| 2014 FY | -176.02 Thousand CAD | -288.11% |
| 2014 Q2 | -36.55 Thousand CAD | 0.63% |
| 2014 Q4 | 2673.00 CAD | 103.21% |
| 2014 Q3 | -83.36 Thousand CAD | -128.07% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 FY | -45.35 Thousand CAD | 0.0% |
| 2013 Q4 | -4656.00 CAD | -212.9% |
| 2013 Q2 | -28.43 Thousand CAD | 0.0% |
| 2013 Q3 | -1488.00 CAD | 94.77% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 100.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 100.0% |
| 2011 FY | -9779.00 CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q2 | -2445.00 CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2009 Q1 | 195.92 Thousand CAD | -34.04% |
| 2009 Q2 | 110.13 Thousand CAD | -43.79% |
| 2009 Q3 | - CAD | -100.0% |
| 2009 FY | - CAD | -100.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2008 Q3 | 156.2 Thousand CAD | 71.4% |
| 2008 Q1 | 210.22 Thousand CAD | 65.49% |
| 2008 FY | 740.29 Thousand CAD | 31.29% |
| 2008 Q4 | 297.03 Thousand CAD | 90.16% |
| 2008 Q2 | 91.13 Thousand CAD | -56.65% |
| 2007 FY | 563.86 Thousand CAD | -11.85% |
| 2007 Q3 | 140.11 Thousand CAD | 61.99% |
| 2007 Q4 | 127.03 Thousand CAD | -9.34% |
| 2007 Q2 | 86.49 Thousand CAD | -76.22% |
| 2007 Q1 | 363.71 Thousand CAD | 339.22% |
| 2006 Q1 | -93.35 Thousand CAD | -122.17% |
| 2006 Q2 | 40.65 Thousand CAD | 143.55% |
| 2006 Q3 | 152.49 Thousand CAD | 275.09% |
| 2006 Q4 | 82.81 Thousand CAD | -45.7% |
| 2006 FY | 639.67 Thousand CAD | 28.14% |
| 2005 FY | 499.21 Thousand CAD | -55.78% |
| 2005 Q4 | 421.12 Thousand CAD | 725.77% |
| 2005 Q3 | 50.99 Thousand CAD | -57.66% |
| 2005 Q2 | 120.44 Thousand CAD | -68.35% |
| 2005 Q1 | 380.55 Thousand CAD | 261.83% |
| 2004 Q1 | - CAD | 0.0% |
| 2004 Q4 | 105.17 Thousand CAD | -76.59% |
| 2004 Q3 | 449.21 Thousand CAD | 131.49% |
| 2004 FY | 1.12 Million CAD | 21.06% |
| 2004 Q2 | 194.05 Thousand CAD | 0.0% |
| 2003 Q1 | -5609.00 CAD | 0.0% |
| 2003 FY | 932.57 Thousand CAD | 153.74% |
| 2003 Q3 | - CAD | 0.0% |
| 2003 Q2 | - CAD | 100.0% |
| 2003 Q4 | - CAD | 0.0% |
| 2002 Q1 | 199.00 CAD | 87.74% |
| 2002 FY | -1.73 Million CAD | -101880.76% |
| 2002 Q3 | 10.78 Thousand CAD | 0.0% |
| 2002 Q4 | - CAD | -100.0% |
| 2002 Q2 | - CAD | -100.0% |
| 2001 FY | 1705.00 CAD | -99.64% |
| 2001 Q3 | 800.00 CAD | 33.33% |
| 2001 Q2 | 600.00 CAD | -96.36% |
| 2001 Q1 | 16.46 Thousand CAD | -71.98% |
| 2001 Q4 | 106.00 CAD | -86.75% |
| 2000 FY | 471.06 Thousand CAD | 481.92% |
| 2000 Q3 | 78.18 Thousand CAD | -60.12% |
| 2000 Q4 | 58.75 Thousand CAD | -24.85% |
| 2000 Q2 | 196.04 Thousand CAD | 293.73% |
| 2000 Q1 | 49.79 Thousand CAD | 4979000.0% |
| 1999 Q2 | 1.00 CAD | -100.0% |
| 1999 Q1 | 130.56 Thousand CAD | 3676.8% |
| 1999 FY | 80.95 Thousand CAD | -44.92% |
| 1999 Q3 | 1.00 CAD | 0.0% |
| 1999 Q4 | 1.00 CAD | 0.0% |
| 1998 Q2 | 10.94 Thousand CAD | 0.0% |
| 1998 Q4 | 3457.00 CAD | 71.48% |
| 1998 FY | 146.97 Thousand CAD | 167.63% |
| 1998 Q3 | 2016.00 CAD | -81.58% |
| 1997 FY | 54.91 Thousand CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | 101.102% |
| Arch Therapeutics, Inc. | -2439.00 USD | -5188.725% |
| CSL Limited | 7.56 Billion USD | 100.002% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.108% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 173.058% |
| BioStem Technologies, Inc. | 15.42 Million USD | 100.836% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 101.342% |
| Qrons Inc. | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 59.628% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 99.5% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 284.274% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -3.816% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -167.291% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 191.809% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.031% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 100.86% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 4258.349% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 101.317% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 296.251% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -277.722% |
| Mesoblast Limited | -35.16 Million USD | 99.633% |
| Marizyme, Inc. | 457.7 Thousand USD | 128.183% |
| Genus plc | 178.7 Million USD | 100.072% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 100.059% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 307.296% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 131.449% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -1072.655% |
| ContraFect Corporation | -154 Thousand USD | 16.239% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -157.984% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 268.044% |
| IMV Inc. | -962.29 Thousand USD | 86.595% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 66.712% |
| MultiCell Technologies, Inc. | 49.32 USD | 261640.957% |
| ONE Bio Corp. | 20.12 Million USD | 100.641% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 100.32% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 363.787% |
| Q BioMed Inc. | -8988.00 USD | -1335.158% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 100.457% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -736.307% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 100.291% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 88.7% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -2504.847% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -32.279% |
| GB Sciences, Inc. | -624.00 USD | -20571.795% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -49.942% |
| HST Global, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Halberd Corporation | -208.00 USD | -61915.385% |
| Enzolytics Inc. | 30.7 Thousand USD | 520.06% |
| Agentix Corp. | - USD | Infinity% |
| Resverlogix Corp. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 126.738% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | 1.1 Billion USD | 100.012% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 74.929% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 120.893% |
| Zenith Capital Corp. | - USD | Infinity% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -1356.549% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -53.838% |
| Kadimastem Ltd | -630.13 Thousand USD | 79.53% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 113.056% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -989.92% |
| Cell Source, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 173.058% |
| NovAccess Global Inc. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 109.505% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -344.8% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 128.662% |
| SYBLEU INC | 11.69 Thousand USD | 1202.873% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 102.799% |
| Bioxytran, Inc. | -8285.00 USD | -1456.934% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 65.418% |
| Neutra Corp. | 14.33 Thousand USD | 999.84% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -57.307% |
| PureTech Health plc | -1.6 Million USD | 91.953% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 87.117% |
| IXICO plc | 3.27 Million USD | 103.945% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 81.413% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 92.798% |
| CSL Limited | 7.7 Billion USD | 100.002% |
| Cellectis S.A. | 18 Thousand USD | 816.622% |